Company
Illudent
- Status
- Operatingas of 2026-09-19
- Business model
- B2B
Claim, correct or request removal
Record updated 28 September 2026
About
Illudent is developing a selective precision medicine to target cancers with a specific set of genetic mutations. The drug is 20 times more deadly to cancer cells harboring these mutations than to normal cells. Funds from their recent raise, led by Ulu Ventures, will enable Illudent to advance its drug to a stage where it is fully ready for clinical trials in approximately 15 months.
Loading relationship preview